Springworks, Merck KGaA

Exclusive-Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics, according to people familiar with the matter.
Merck KGaA in Talks to Buy SpringWorks Therapeutics
Merck KGaA is in advanced talks to buy US cancer and rare diseases drugmaker SpringWorks Therapeutics Inc., according to a report from Reuters, citing people familiar with the matter.
SpringWorks Therapeutics jumps on report of Merck KGaA takeover talks (update)
SpringWorks Therapeutics ( NASDAQ: SWTX) soared ~40% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions to acquire the cancer and rare disease drugmaker.
Merck KGaA confirms ‘advanced’ talks to acquire SpringWorks
Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms
Merck KGaA sets its sights on acquisition of Ogsiveo-maker SpringWorks: Reuters
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker appears to have attracted the attention of a biopharma bigwig from o | Merck KGaA is said to be in advanced talks to acquire cancer and are disease specialist SpringWorks,
Merck's Bold Move: Eyes on Springworks in Potential $4 Billion Acquisition
Merck KGaA is in advanced negotiations to acquire U.S.-based Springworks Therapeutics, a move that could rank among the largest pharma deals for Merck. This potential acquisition aims to boost Merck's cancer treatment pipeline amidst a challenging landscape for the German healthcare giant.
SpringWorks shares up 39% to $55.90 after Merck KGaA confirms talks
EST SpringWorks shares up 39% to $55.90 after Merck KGaA (MKGAY) confirms talksMaximize Your Portfolio with Data Driven Insights:Leverage
Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works
German pharma company Merck KGaA confirmed that it is in talks to acquire SpringWorks Therapeutics, though a deal has yet to be announced.
Springworks surges as Germany's Merck KGaA said to be targeting takeover
Shares of Springworks Therapeutics (NASDAQ: SWTX) surged over 37% on Monday following reports that Germany’s Merck (NSE: PROR) KGaA is in advanced talks to acqu
EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition
Merck KGaA (“Merck”) reacts to press reports and confirms advanced discussions with Springworks Therapeutics, Inc. Merck also confirms that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize.
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company. Shares were trading around $54.66. The stock is up 16% over the last year and hit a new 52-week high earlier in the session.
Merck KGaA verhandelt Milliardendeal mit US-Tumorspezialisten
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...
devdiscourse8h
Merck's Ambitious Pursuit of SpringWorks: A Strategic Bet in Oncology
Merck KGaA is in advanced talks to acquire SpringWorks Therapeutics, aiming to expand its cancer treatment pipeline. While no binding agreement exists yet, a potential deal is seen as strategically ...
Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200
We recently compiled a list of the Morgan Stanley's 15 Best European AI Stocks. In this article, we are going to take a look ...
Goldman Sachs Sticks to Their Buy Rating for Merck KGaA (0O14)
Goldman Sachs analyst James Quigley maintained a Buy rating on Merck KGaA (0O14 – Research Report) today and set a price target of €185.00. The ...
Cosmetics Business21h
High performance meets metallic magic with Ronaflux® cosmetic pigments
EMD Electronics, the North American pigments division of Merck KGaA, Darmstadt, Germany, has launched Ronaflux® cosmetic ...
FierceBiotech21h
Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger
Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...